Amedisys (Nasdaq: AMED) is expected to report Q2 earnings on July 31. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Amedisys's revenues will wither -13.3% and EPS will wither -63.0%.

The average estimate for revenue is $328.0 million. On the bottom line, the average EPS estimate is $0.10.

Revenue details
 Last quarter, Amedisys booked revenue of $339.2 million. GAAP reported sales were 8.2% lower than the prior-year quarter's $365.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $0.13. GAAP EPS of $0.09 for Q1 were 50% lower than the prior-year quarter's $0.18 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 42.6%, 30 basis points worse than the prior-year quarter. Operating margin was 1.2%, 220 basis points worse than the prior-year quarter. Net margin was 0.8%, 70 basis points worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $1.32 billion. The average EPS estimate is $0.47.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 805 members out of 891 rating the stock outperform, and 86 members rating it underperform. Among 212 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 186 give Amedisys a green thumbs-up, and 26 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Amedisys is hold, with an average price target of $10.67.

Is Amedisys the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.